Breen Michael Martin 4
4 · GT Biopharma, Inc. · Filed Nov 12, 2021
Insider Transaction Report
Form 4
Breen Michael Martin
Director
Transactions
- Award
Common Stock
2021-02-16+278,058→ 278,058 total - Conversion
Common Stock
2021-02-25$3.40/sh+9,859$33,521→ 328,160 total - Conversion
10% Senior Convertible Debenture
2021-02-25−30,000→ 0 totalExercise: $3.40From: 2020-06-23Exp: 2021-06-23→ Common Stock (9,859 underlying) - Conversion
Common Stock
2021-02-25$3.40/sh+40,243$136,826→ 318,301 total - Award
Option to purchase Common Stock
2021-02-16+50,000→ 50,000 totalExercise: $6.33Exp: 2031-02-15→ Common Stock (50,000 underlying) - Conversion
10% Senior Convertible Debenture
2021-02-25−100,000→ 0 totalExercise: $3.40From: 2018-09-07→ Common Stock (40,243 underlying)
Footnotes (3)
- [F1]Represents a grant of shares of restricted stock ("RSAs"). 1/3rd of the RSAs vest on January 13, 2021, 2022 and 2023.
- [F2]1/3rd of the shares vest on February 16, 2021, 2022 and 2023.
- [F3]While the maturity date of the Debenture was September 7, 2019, the Registrant did not repay the Debenture on the maturity date and the Debenture remained outstanding until converted.